Advertisement

Topics

Novartis International AG: AveXis data reinforce effectiveness of Zolgensma in treating spinal muscular atrophy (SMA) Type 1

16:53 EDT 16 Apr 2019 | FinanzNachrichten

Novartis International AG / AveXis data reinforce effectiveness of Zolgensma in treating spinal muscular atrophy (SMA) Type 1 . Processed and transmitted by West Corporation. The issuer is solely r...

Original Article: Novartis International AG: AveXis data reinforce effectiveness of Zolgensma in treating spinal muscular atrophy (SMA) Type 1

NEXT ARTICLE

More From BioPortfolio on "Novartis International AG: AveXis data reinforce effectiveness of Zolgensma in treating spinal muscular atrophy (SMA) Type 1"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...